China Biopharmaceutical,

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

  • Product Code
  • ILEA000293090
  • Registered date
  • 2020/12/26 00:00:00
  • Credit
  • CFOTO / Kyodo News Images
  • Media source
  • Liu Huaiyu / CFOTO
  • Media size
  • 4752 × 3168 pixel
  • Resolution
  • 72 dpi
  • Deployment size
  • 1.40(MB)*
  • Special instruction
  • China Out
    **The text may be generated by an automatic translation system**

*File size when opened in Photoshop, etc.

Similar Images & Videos
    China Biopharmaceutical,

    China Biopharmaceutical,

    Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.
      China Biopharmaceutical,

      China Biopharmaceutical,

      Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.
        China Biopharmaceutical,

        China Biopharmaceutical,

        Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.
          China Biopharmaceutical,

          China Biopharmaceutical,

          Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.
            China Biopharmaceutical,

            China Biopharmaceutical,

            Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.
              China Biopharmaceutical,

              China Biopharmaceutical,

              Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.
                China Biopharmaceutical,

                China Biopharmaceutical,

                Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.
                  China Biopharmaceutical,

                  China Biopharmaceutical,

                  Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.
                    China Biopharmaceutical,

                    China Biopharmaceutical,

                    Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.
                      China Biopharmaceutical,

                      China Biopharmaceutical,

                      Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.